Stay updated on Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.

Latest updates to the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page
- Check7 days agoChange DetectedPrimary completion and study completion are now estimated for 2026-12-31, and enrollment is updated to 24 participants. Recent update dates (2026-02-13 and 2026-02-17) were added and an older date (2026-02-28) was removed.SummaryDifference0.3%

- Check13 days agoChange DetectedRevision: v3.4.2 added; the prior funding-lapse notice (v3.4.1) was removed.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a government funding lapse notice affecting site updates and a page revision note showing version v3.4.1, replacing the previous v3.4.0.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded Show glossary option and a display of Last Update Submitted that Met QC Criteria, along with a Revision: v3.4.0 and a No FEAR Act Data entry. Removed Last Update Submitted that met QC Criteria, No FEAR Act data, and the older Revision: v3.3.4.SummaryDifference0.2%

- Check42 days agoChange DetectedA minor revision update from v3.3.3 to v3.3.4 is shown; there are no apparent changes to the study details, eligibility criteria, or other content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Locations section with Texas as the study site. The page revision updated to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.